MITSUBISHI TANABE PHARMA CORPORATION

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety and Efficacy of MT-4666

Phase 2

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Placebo
Drug: MT-4666

First Posted Date: 2013-01-09

Last Posted Date: 2015-09-28

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 450

Registration Number: NCT01764243

A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria

Phase 2

Completed

Conditions: Diabetic Nephropathy

Interventions: Drug: Placebo
Drug: MT-3995 Low
Drug: MT-3995 High

First Posted Date: 2012-12-27

Last Posted Date: 2015-02-09

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 67

Registration Number: NCT01756703

Locations: 🇸🇰
Investigational site, Zilina, Slovakia

A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria and Moderately Decreased GFR

Phase 2

Completed

Conditions: Diabetic Nephropathy

Interventions: Drug: MT-3995 High
Drug: Placebo
Drug: MT-3995 Low

First Posted Date: 2012-12-27

Last Posted Date: 2015-02-09

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 49

Registration Number: NCT01756716

Locations: 🇸🇰
Investigational site, Sturovo, Slovakia

Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C

Phase 3

Completed

Conditions: Chronic Hepatitis C (CHC)

Interventions: Drug: MP-424
Drug: RBV
Drug: PEG-IFN alfa-2a

First Posted Date: 2012-12-20

Last Posted Date: 2016-10-03

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 54

Registration Number: NCT01753557

Locations: 🇯🇵
Toranomon Hospital, Kawasaki City, Takatsu-ku, Japan

Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)

Phase 3

Completed

Conditions: Chronic Hepatitis C(CHC)

Interventions: Drug: RBV(48 weeks)
Drug: MP-424
Drug: IFN beta(48 weeks)
Drug: RBV(24 weeks)
Drug: IFN beta(24 weeks)

First Posted Date: 2012-12-20

Last Posted Date: 2018-10-26

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 74

Registration Number: NCT01753570

Locations: 🇯🇵
Toranomon Hospital, Kawasaki City, Takatsu-ku, Japan

Dose-finding Study of MT-1303

Phase 2

Completed

Conditions: Relapsing-remitting Multiple Sclerosis

Interventions: Drug: MT-1303-Low
Drug: MT-1303-Middle
Drug: Placebo
Drug: MT-1303-High

First Posted Date: 2012-12-05

Last Posted Date: 2016-09-14

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 415

Registration Number: NCT01742052

Locations: 🇬🇧
Research Site, London, United Kingdom

A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis

Phase 3

Completed

Conditions: Pustular Psoriasis (Excluding a Localized)
Plaque Psoriasis
Psoriatic Arthritis
Psoriatic Erythroderma

Interventions: Drug: TA-650

First Posted Date: 2012-09-07

Last Posted Date: 2017-03-13

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 51

Registration Number: NCT01680159

Locations: 🇯🇵
Investigational site, Tohoku, Japan

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of MT-1303 in Subjects With Inflammatory Bowel Disease

Phase 1

Completed

Conditions: Inflammatory Bowel Disease

Interventions: Drug: MT-1303

First Posted Date: 2012-08-16

Last Posted Date: 2014-09-05

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 18

Registration Number: NCT01666327

Locations: 🇬🇧
Research Site, Nottingham, United Kingdom

Long-Term Study of MP-214 in Patients With Schizophrenia

Phase 2

Completed

Conditions: Schizophrenia

Interventions: Drug: Risperidone 4mg
Drug: MP-214 9mg
Drug: MP-214 3mg
Drug: MP-214 6mg

First Posted Date: 2012-06-25

Last Posted Date: 2021-04-12

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 254

Registration Number: NCT01626872

A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia

Phase 2

Completed

Conditions: Schizophrenia

Interventions: Drug: MP-214 3mg
Drug: MP-214 6mg
Drug: MP-214 9mg

First Posted Date: 2012-06-25

Last Posted Date: 2021-04-12

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 38

Registration Number: NCT01626859

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy